Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

Delayed Quote. Delayed  - 10/25 04:59:42 pm
276.9 DKK   -1.84%
08:21p NOVO NORDISK A/ : submits application to regulatory authorities to i..
10/19 NOVO NORDISK A/ : - Share repurchase programme
10/18 NOVO NORDISK A/ : Alvogen scores in Barcelona
News SummaryMost relevantAll newsSector news 

Novo Nordisk B : In Kenya, Novo Nordisk tests a new business model to improve access to insulin (13 April 2012)

share with twitter share with LinkedIn share with facebook
share via e-mail
04/13/2012 | 10:15am CEST
News In Kenya, Novo Nordisk tests a new business model to improve access to insulin (13 April 2012)

As part of an official Danish state visit to Kenya, Novo Nordisk on 12 April officially launched a programme to make insulin and diabetes care more accessible to poor populations.

In Kenya, 250,000 people are in need of insulin out of which 80,000 are people with an annual income between 1,500-3,000 US dollars. To make insulin more affordable and accessible to this group, Novo Nordisk has in partnership with local organisations and faith-based hospitals and clinics developed a new business model that includes a streamlined supply chain and treatment centres that are closer to the patients' homes.

The project has reduced price mark-ups in the supply chain to the extent that the insulin can be obtained at 20 cents daily, which is equivalent to a third of the previous price on the private market.

The Kenyan project is the first of three pilots to be launched by Novo Nordisk this year. A second one is about to be launched in India, and a third pilot will be launched in Nigeria later in 2012.

The pilot projects will create valuable learnings on how access to insulin and proper diabetes care can be improved for people with diabetes with very low incomes.

Worldwide, there is a population of 46 million people with diabetes who earn between 4 and 10 dollars per day. In 2030, this group is expected to grow to more than 73 million people.

Diabetes in Africa

According to the International Diabetes Federation, the growth of diabetes in Africa is currently the highest in the world. Close to 15 million people in sub-Saharan Africa currently have diabetes, and this number is expected to rise to around 28 million in 2030. It is estimated that 78% of people with diabetes today are undiagnosed.

In Kenya, the International Diabetes Federation estimates that there are currently around one million people with diabetes in Kenya with urban prevalence up to 10%.

Video from Kenya will be available here Monday.

Contacts details:

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on NOVO NORDISK A/S
08:21p NOVO NORDISK A/S : submits application to regulatory authorities to include LEAD..
10/19 NOVO NORDISK A/S : - Share repurchase programme
10/18 NOVO NORDISK A/S : Alvogen scores in Barcelona
10/13 NOVO NORDISK A/S : New Immunoglobulins Study Findings Recently Were Reported by ..
10/13 NOVO NORDISK A/S : Patent Issued for Method and Apparatus for Assisting Patients..
10/10 NOVO NORDISK A/S : aktietilbagekøbsprogram
10/10 NOVO NORDISK A/S : - Share repurchase programme
10/10 NOVO NORDISK A/S : receives Complete Response Letter in the US for faster-acting..
10/07 NOVO NORDISK A/S : receives Complete Response Letter in the US for faster-acting..
10/07DJInsulin List-Prices Climb Even as Drugmakers' Share Stays Flat
More news
Sector news : Pharmaceuticals - NEC
08:05pDJMERCK : Profit Rises on Cancer Drugs, Vaccines
07:48pDJMERCK : Revenue and Profit Rise on Cancer Drugs, Vaccines -- Update
06:12p ChemChina ready for concessions to clinch delayed Syngenta deal in 2017 - sou..
01:59pDJMERCK : Revenue and Profit Rise on Cancer Drugs, Vaccines
01:53pDJMARKET SNAPSHOT : U.S. Stock Futures Point To Modest Gains, With Apple Set To Ta..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
10/23 How The Yield On Cost Can Be Misleading
10/17 Amazon - Next Stop $100 Or $1000?
10/17 Tracking Ken Fisher's Fisher Asset Management Portfolio - Q3 2016 Update
10/13 What's Going On With Novo Nordisk?
10/13 Dangerous, One-Sided, All-In Market
Financials ( DKK)
Sales 2016 112 810 M
EBIT 2016 49 019 M
Net income 2016 38 023 M
Finance 2016 10 835 M
Yield 2016 2,52%
P/E ratio 2016 18,74
P/E ratio 2017 17,28
EV / Sales 2016 4,94x
EV / Sales 2017 4,66x
Capitalization 567 744 M
More Financials
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | NOVO B | DK0060534915 | 4-Traders
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus HOLD
Number of Analysts 32
Average target price 341  DKK
Spread / Average Target 21%
Consensus details
EPS Revisions
More Estimates Revisions
Lars Rebien Sørensen President & Chief Executive Officer
Göran Albert Ando Chairman
Jesper Brandgaard Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Alan C. Moses Global Chief Medical Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S-29.08%83 068
JOHNSON & JOHNSON10.60%310 823
ROCHE HOLDING LTD.-15.88%200 485
NOVARTIS AG-13.71%197 285
PFIZER INC.-0.46%194 889
MERCK & CO., INC.15.01%167 986
More Results